Tech Company Financing Transactions
Priothera Funding Round
On 6/24/2025, Priothera secured $2 million in funding from Bpifrance.
Transaction Overview
Company Name
Announced On
6/24/2025
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding will support Priothera's clinical programme to evaluate whether adding mocravimod to commercial CAR-T cell therapies could improve patient outcomes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
57 Avenue Général de Gaulle
Saint-Louis, 68300
France
Saint-Louis, 68300
France
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers, in addition to cellular therapies such as hematopoietic cell transplantation and CAR-T cell therapies. Mocravimod is being developed as an adjunctive and maintenance therapy for hematological malignancies requiring allogeneic hematopoietic cell transplant (allo-HCT), focusing initially on acute myeloid leukemia (AML).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Florent Gros
Browse more venture capital transactions:
Prev: 6/24/2025: Paraform venture capital transaction
Next: 6/24/2025: Ledgebrook venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs